Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MB 7133

Next Previous
Drug Profile

MB 7133

Alternative Names: MB-07133; MB-7133

Latest Information Update: 27 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Metabasis Therapeutics
  • Developer Ligand Pharmaceuticals; Xian Xintong Pharmaceutical Research
  • Class Antineoplastics; Furans; Phosphorus compounds; Pyrimidines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Liver cancer

Most Recent Events

  • 18 Jan 2022 Phase-I/II clinical trials in Liver cancer (In the elderly, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater, In adults, Combination therapy) in China (IV) (NCT06141109)
  • 28 Jan 2021 No recent reports of development identified for phase-I development in Liver-cancer(Inoperable/Unresectable) in China (IV, Infusion)
  • 08 Nov 2019 Efficacy and adverse events data from a phase I trial in Liver cancer presented at the presented at the 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top